Short Interest in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Declines By 33.4%

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 8,407 shares, a drop of 33.4% from the June 30th total of 12,617 shares. Approximately 4.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,362 shares, the days-to-cover ratio is presently 3.6 days.

Amplify Weight Loss Drug & Treatment ETF Stock Up 0.3%

Shares of THNR opened at $25.86 on Friday. Amplify Weight Loss Drug & Treatment ETF has a 52-week low of $21.70 and a 52-week high of $27.28. The stock has a market cap of $5.17 million, a PE ratio of 24.31 and a beta of 0.37. The firm’s fifty day moving average is $25.16 and its two-hundred day moving average is $25.16.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC acquired a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.